Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
Montreal Heart Institute, 5000 Bélanger, Room S-6300, Montreal, QC, Canada H1T 1C8.
Can J Gastroenterol Hepatol. 2018 Jun 13;2018:7439730. doi: 10.1155/2018/7439730. eCollection 2018.
The objective of this literature review was to evaluate the existing evidence regarding the cost-effectiveness of treatment options in IBD.
A systematic review of the literature was conducted to identify economic evaluations of IBD therapy. The literature search was performed using electronic databases MEDLINE and EMBASE. Searches were limited to full economic evaluations published in English or French between 2004 and 2016.
A total of 5,403 potentially relevant studies were identified. After screening titles and abstracts, 48 studies were included, according to the eligibility criteria. A total of 56% and 42% of the studies were assessing treatments of UC or CD, respectively. Treatment options under evaluation included biological agents, mesalamine, immunosuppressants, and surgery. The majority of studies evaluated the cost-effectiveness of biological treatments. Biological therapies were dominant in 23% of the analyses and were cost-effective according to a $CAD50,000/QALY and $CAD100,000/QALY threshold in 41% and 62% of the analyses, respectively.
This literature review provided a comprehensive overview of the economic evaluations for the different treatment options for IBD over the past 12 years and represents a helpful reference for future economic evaluations.
本次文献回顾旨在评估 IBD 治疗方案的成本效益的现有证据。
对 IBD 治疗的经济评估进行了系统的文献回顾。文献检索使用了 MEDLINE 和 EMBASE 电子数据库。检索范围限于 2004 年至 2016 年间以英文或法文发表的全成本效益评估。
共确定了 5403 项潜在相关研究。根据入选标准，经过标题和摘要筛选后，共纳入 48 项研究。分别有 56%和 42%的研究评估了 UC 或 CD 的治疗方法。评估的治疗方案包括生物制剂、美沙拉嗪、免疫抑制剂和手术。大多数研究评估了生物治疗的成本效益。在 23%的分析中，生物疗法占主导地位，根据加元 50000 美元/QALY 和加元 100000 美元/QALY 的阈值，分别有 41%和 62%的分析认为其具有成本效益。
本次文献回顾提供了过去 12 年 IBD 不同治疗方案的经济评估的全面概述，是未来经济评估的有益参考。
